Boothbay Fund Management, LLC Assembly Biosciences, Inc. Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.35 - $2.29 $28,900 - $49,024	-21,408 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.14 - $3.9 $825 - $1,025	263 Added 1.24%	21,408 $74,000
Q2 2021 Aug 16, 2021	BUY	$3.8 - $4.56 $34,219 - $41,062	9,005 Added 74.18%	21,145 $82,000
Q1 2021 May 17, 2021	SELL	$4.33 - $6.63 $36,003 - $55,128	-8,315 Reduced 40.65%	12,140 $56,000
Q4 2020 Feb 12, 2021	SELL	$4.87 - $17.29 $38,623 - $137,126	-7,931 Reduced 27.94%	20,455 $124,000
Q3 2020 Nov 16, 2020	SELL	$15.08 - $27.04 $1.19 Million - $2.14 Million	-78,992 Reduced 73.56%	28,386 $467,000
Q2 2020 Aug 14, 2020	BUY	$14.57 - $23.96 $14,570 - $23,960	1,000 Added 0.94%	107,378 $2.5 Million
Q1 2020 May 15, 2020	SELL	$10.27 - $21.23 $205,400 - $424,600	-20,000 Reduced 15.83%	106,378 $1.58 Million
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $219,115 - $624,060	26,210 Added 26.17%	126,378 $2.59 Million
Q3 2019 Nov 14, 2019	BUY	$9.83 - $14.82 $56,551 - $85,259	5,753 Added 6.09%	100,168 $985,000
Q2 2019 Aug 14, 2019	BUY	$12.9 - $20.8 $1.22 Million - $1.96 Million	94,415 New	94,415 $1.27 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $737M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.